BridgeBio Pharma Director Makes a Multi-Million Dollar Stock Move!

New insider activity at BridgeBio Pharma ( (BBIO) ) has taken place on November 7, 2025.

Director Ronald J. Daniels has recently executed a significant transaction involving BridgeBio Pharma stock. Daniels sold a total of 61,031 shares, which amounted to a substantial $3,888,895. This move highlights a notable shift in stock ownership within the company.

Recent Updates on BBIO stock

BridgeBio Pharma has seen several analysts raise their price targets following its recent Q3 earnings call and positive clinical trial results. Goldman Sachs increased its target due to strong commercial momentum for Attruby, with U.S. sales exceeding estimates and a significant increase in prescriptions. The firm highlighted BridgeBio’s growing market share among newly diagnosed ATTR-CM patients and its strategic investments in awareness and diagnosis expansion. Truist raised its target reflecting Attruby’s Q3 performance and positive Phase 3 data for ribitol in LGMD2I/R9 and encaleret in ADH1. TD Cowen cited a 51% quarter-over-quarter growth in Attruby sales, driven by treatment-naive patients and new prescriptions, as reasons for its target increase. Overall, BridgeBio’s successful clinical trials, robust financial performance, and strategic growth initiatives have contributed to a positive outlook, despite challenges in market access and rising operating expenses.

Spark’s Take on BBIO Stock

According to Spark, TipRanks’ AI Analyst, BBIO is a Neutral.

BridgeBio Pharma’s overall stock score is driven by strong earnings call results and technical momentum, offset by financial instability and poor valuation metrics. The company’s growth potential is evident, but significant risks remain due to high leverage and cash flow challenges.

To see Spark’s full report on BBIO stock, click here.

More about BridgeBio Pharma

YTD Price Performance: 122.45%

Average Trading Volume: 2,392,113

Technical Sentiment Signal: Buy

Current Market Cap: $12.08B